Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: A Hellenic Co-operative Oncology Group (HeCOG) study

Gynecologic Oncology

Volumn 110, Issue 1, 2008, Pages 87-92

  Papadimitriou, Christos A ^a   Bafaloukos, Dimitrios ^b   Bozas, George ^a   Kalofonos, Haralambos ^c   Kosmidis, Paris ^d   Aravantinos, Gerassimos ^e   Fountzilas, George ^f   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b METROPOLITAN HOSPITAL   (Greece)

^c UNIVERSITY OF PATRAS   (Greece)

^d Ygeia Hospital   (Greece)

^e AGII ANARGIRI CANCER HOSPITAL   (Greece)

^f ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Carboplatin; Epirubicin; Metastatic endometrial cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; RANITIDINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG ACTIVITY; ENDOMETRIUM CARCINOMA; FEBRILE NEUTROPENIA; HEART DEATH; HUMAN; MAJOR CLINICAL STUDY; NEUROTOXICITY; OUTPATIENT CARE; PRIORITY JOURNAL;

ADENOCARCINOMA; ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, PAPILLARY; ENDOMETRIAL NEOPLASMS; EPIRUBICIN; FEMALE; GREECE; HUMANS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PATIENT SELECTION; RECURRENCE;

EID: 45549092188     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.03.004     Document Type: Article

References (41)

1. Rose P.G. Endometrial carcinoma. N Engl J Med 335 (1996) 640-649
2. Bremond A., Bataillard A., Thomas L., Achard J.L., Fervers B., Fondrinier E., et al. Cancer of the endometrium. Br J Cancer 84 (2001) 31-36
3. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
4. Muss H. Chemotherapy of metastatic endometrial cancer. Semin Oncol 21 (1994) 107-113
5. Pectasides D., Pectasides E., and Economopoulos T. Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev 33 (2007) 177-190
6. Amant F., Moerman P., Neven P., Timmerman D., van Limbergen E., and Vergote I. Treatment modalities in endometrial cancer. Curr Opin Oncol 19 (2007) 479-485
7. Fleming G.F. Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol 25 (2007) 2983-2990
8. Ball H.G., Blessing J.A., Lentz S.S., and Mutch D.G. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 62 (1996) 278-281
9. Lissoni A., Zanetta G., Losa G., Gabriele A., Parma G., and Mangioni C. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol 7 (1996) 861-863
10. Woo H.L., Swenerton K.D., and Hoskins P.J. Taxol is active in platinum-resistant endometrial adenocarcinoma. Am J Clin Oncol 19 (1996) 290-291
11. Thigpen J.T., Buchsbaum H., Mangan C., and Blessing J.A. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep 63 (1979) 21-27
12. Thigpen J.T., Blessing J.A., Homesley H., Creasman W.T., and Sutton G. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 33 (1989) 68-70
13. Burke T.W., Munkarah A., Kavanagh J.J., Morris M., Levenback C., Tornos C., et al. Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol Oncol 51 (1993) 397-400
14. Thigpen T., Vance R., and Khansur T. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Semin Oncol 22 (1995) 67-75
15. Sledge G.W., Neuberg D., Bernardo P., Ingle J.N., Martino S., and Rowinsky E.K. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21 (2003) 588-592
16. Thigpen J.T., Blessing J.A., DiSaia P.J., Yordan E., Carson L.F., and Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma. J Clin Oncol 12 (1994) 1408-1414
17. Thigpen J.T., Brady M.F., Homesley H.D., Malfetano J., DuBeshter B., Burger R.A., et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 22 (2004) 3902-3908
18. Aapro M.S., van Wijk F.H., Bolis G., Chevallier B., van der Burg M.E.L., Poveda A., et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 14 (2003) 441-448
19. McGuire III W.P. Current status of taxane and platinum-based chemotherapy in ovarian cancer. J Clin Oncol 21 10 Suppl (2003) 133s-135s
20. Cannistra S.A. Cancer of the ovary. N Engl J Med. 351 (2004) 2519-2529
21. Fleming G.F., Fowler J.M., Waggoner S.E., Copeland L.J., Greer B.E., Horowitz I., et al. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study. J Clin Oncol 19 (2001) 1021-1029
22. Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22 (2004) 2159-2166
23. Dimopoulos M.A., Papadimitriou C.A., Georgoulias V., Moulopoulos L.A., Aravantinos G., Gika D., et al. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gynecol Oncol 78 (2000) 52-57
24. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334 (1996) 1-6
25. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1991) 207-214
26. Hryniuk K.W.M., and Goodyear M. The calculation of received dose intensity. J Clin Oncol 8 (1990) 1935-1937
27. Coppin C.M. The description of chemotherapy delivery options and pitfalls. Semin Oncol 14 Suppl 14 (1987) 32-42
28. Lentner C. Geigy scientific tables ('exact confidence limits for p'). (1982), Ciba-Geigy, Switzerland 89-102
29. Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assos 53 (1958) 457-481
30. Cox D. Regression models and life tables (with discussion). J Royal Stat Soc B 34 (1972) 187-220
31. Humber C.E., Tierney J.F., Symonds R.P., Collingwood M., Kirwan J., Williams C., et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol. 18 (2007) 409-420
32. Gianni L., Munzone E., Capri G., Fulfaro F., Tarenzi E., Villani F., et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13 (1995) 2688-2699
33. Connelly E., Markman M., Kennedy A., Webster K., Kyle B., Peterson G., et al. Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol 62 (1996) 166-168
34. Papadimitriou C.A., Sarris K., Moulopoulos L.A., Fountzilas G., Anagnostopoulos A., Voulgaris Z., et al. Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. J Clin Oncol 17 (1999) 761-766
35. DuBois A., Lueck H.J., Meier W., Adams H.P., Moebus V., Costa S., et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95 (2003) 1320-1329
36. Pignata S., De Placido S., Biamonte R., Scambia G., Di Vagno G., Colucci G., et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer 6 (2006) 5
37. Lissoni A., Gabriele A., Gorga G., Tumolo S., Landoni F., Mangioni C., et al. Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma. Ann Oncol 8 (1997) 969-972
38. Sovak M.A., Dupont J., Hensley M.L., Ishill N., Gerst S., Abu-Rustum N., et al. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int J Gynecol Cancer 17 (2007) 197-203
39. Du Bois A., Weber B., Rochon J., Meier W., Goupil A., Olbricht S., et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 24 (2006) 1127-1135
40. Zipes D.P., and Wellens H.J. Sudden cardiac death. Circulation. 98 (1998) 2334-2351
41. Myerburg R.J., Kessler K.M., and Castellanos A. Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation 85 (1992) I2-I10